Abcam, ab251547, Anti-NAGLU/NAG antibody [EPR20708] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal NAGLU/NAG antibody. Carrier free. Suitable for ICC/IF, WB, Flow Cyt (Intra), IHC-P and reacts with Mouse, Human, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20708,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:Flow Cyt (Intra), ICC/IF, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251547 is the carrier-free version of
ab214671
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
NAGLU/NAG also known as alpha-N-acetylglucosaminidase is an enzyme with a molecular weight of approximately 83 kDa. This enzyme localizes in the lysosome where cells express it across various tissues. NAGLU plays a significant role in the breakdown of heparan sulfate which is a glycosaminoglycan found on cell surfaces and in the extracellular matrix. Its enzymatic action involves the cleavage of terminal alpha-N-acetylglucosamine residues during lysosomal degradation.
Biological function summary
NAGLU facilitates the degradation of heparan sulfate in conjunction with other enzymes as part of a degradation complex within the lysosome. NAGLU's action is essential for maintaining the balance of heparan sulfate levels inside cells which is important for cellular health and function. Without the proper function of this enzyme heparan sulfate accumulates within lysosomes due to incomplete catabolism leading to cellular dysfunction and related pathologies.
Pathways
NAGLU functions critically in the glycosaminoglycan degradation pathway. This pathway involves several enzymes including iduronate-2-sulfatase which acts upstream of NAGLU. Together they ensure the breakdown of complex sugars such as heparan sulfate. NAGLU also participates in the larger lysosomal degradation pathway collaborating with other lysosomal enzymes to ensure proper breakdown and recycling of cellular materials.
Disruptions in NAGLU function are directly linked to mucopolysaccharidosis type IIIB (MPS IIIB) also known as Sanfilippo syndrome type B. This disorder results from mutations that impair NAGLU activity causing heparan sulfate accumulation and neurodegeneration. Additionally deficient NAGLU activity may intersect with pathologies involving heparan sulfate binding proteins impacting cellular signaling and contributing to disease progression.